PT-141, scientifically known as Bremelanotide, is a synthetic cyclic heptapeptide and α-MSH analogue that acts as a potent melanocortin receptor agonist . Unlike traditional treatments targeting blood flow, it works directly on the central nervous system by activating MC3 and MC4 receptors, regulating sexual desire pathways .

In 2019, the FDA approved its brand name Vyleesi for premenopausal women with Hypoactive Sexual Desire Disorder (HSDD), addressing distressing low libido when other therapies fail . Clinical studies confirm efficacy for both genders, aiding erectile dysfunction in men and sexual arousal disorder in women .

Available as nasal sprays or high-purity (≥97%) powder, it offers convenient administration—typically 45 minutes before activity . With a molecular formula of C₅₀H₆₈N₁₄O₁₀ and weight of 1025.2 g/mol, it ensures stability under proper storage . A safer alternative to PDE5 inhibitors, it redefines sexual health treatment .

Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabled as a drug, food or cosmetic.